Recent trials reported that risk of atrial fibrillation (AF) is increased in patients using
ivabradine compared with controls. We performed this meta‐analysis to investigate the risk …

Objective To quantify any risk of atrial fibrillation (AF) associated with ivabradine treatment
by meta-analysis of clinical trial data. Methods Medline, Embase, Web of Knowledge and the …

Coronary artery disease (CAD) and heart failure (HF) are major worldwide threat to health
and well-being. Important progress in the treatment of CAD and HF have contributed to a …

In Europe, ivabradine has recently been approved to treat patients with angina who have
intolerance to beta blockers and/or heart failure. Ivabradine is considered to act specifically …

Introduction In patients with acute decompensated systolic heart failure (ADSHF) high
resting heart rate (HR) could be either a compensatory mechanism or contribute to …

Background: Tachycardia is a hallmark of sepsis. An elevated heart rate could impair
ventricular filling and increase myocardial oxygen demand. β-Blockers and ivabradine (a …

Elevated heart rate could negatively influence cardiovascular risk in the general population.
It can induce and promote the atherosclerotic process by means of several mechanisms …

Life-threatening ventricular arrhythmias, such as ventricular tachycardia and ventricular
fibrillation remain an ongoing clinical problem and their prevention and treatment require …

Background: Ivabradine is a novel specific heart rate (HR)-lowering agent that improves
event-free survival in patients with heart failure (HF). Objectives: We aimed to evaluate the …

Background Heart rate is a major determinant of myocardial oxygen demand; in ST-segment
elevation myocardial infarction (STEMI), patients treated with primary percutaneous …